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Abstract
Osteoarthritis is characterized by a loss of articular cartilage homeostasis in which degradation 
exceeds formation. Several growth factors have been shown to promote cartilage formation by 
augmenting articular chondrocyte anabolic activity. This study tests the hypothesis that such 
growth factors also play an anti-catabolic role. We transferred individual or combinations of the 
genes encoding insulin- like growth factor I, bone morphogenetic protein-2, bone morphogenetic 
protein-7, transforming growth factor-β1 and fibroblast growth factor-2, into adult bovine articular 
chondrocytes and measured the expression of catabolic marker genes encoding A disintegrin and 
metalloproteinase with thrombospondin motifs-4 and −5, matrix metalloproteinases-3 and −13, 
and interleukin-6. When delivered individually, or in combination, these growth factor transgenes 
differentially regulated the direction, magnitude and time course of expression of the catabolic 
marker genes. In concert, the growth factor transgenes regulated the marker genes in an interactive 
fashion that ranged from synergistic inhibition to synergistic stimulation. Synergistic stimulation 
prevailed over synergistic inhibition, reaching maxima of 15.2-fold and 2.7-fold, respectively. 
Neither the magnitude nor the time course of the effect of the transgene combinations could be 
predicted on the basis of the individual transgene effects. With few exceptions, the data contradict 
our hypothesis. The results demonstrate that growth factors that are traditionally viewed as 
chondrogenic tend also to promote catabolic gene expression. The competing actions of these 
potential therapeutic agents add an additional level of complexity to the selection of regulatory 
factors for restoring articular cartilage homeostasis or promoting repair.
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Introduction
Articular cartilage loss in osteoarthritis reflects a disruption of normal homeostasis. The 
balanced matrix turnover of healthy cartilage is replaced by greater matrix degradation than 
formation, resulting in a net loss of cartilage tissue and impaired joint function. One 
approach to articular cartilage repair is to reverse this imbalance (Trippel, 1995). This 
approach may be accomplished by augmenting chondrocyte anabolic and mitotic activity, or 
suppressing chondrocyte catabolic activity, or both. Several polypeptide growth factors have 
been shown to augment articular chondrocyte anabolic or mitotic activity (Chopra and 
Anastassiades, 1998; Guerne et al., 1994; Trippel, 1997). These include insulin-like growth 
factor-I (IGF-I) (Sah et al., 1994; Fortier, Mohammed et al., 2002; Luyten et al., 1988), 
fibroblast growth factor-2 (FGF- 2) (Sah et al., Kato et al., 1987; Henson et al., 2005), bone 
morphogenetic protein-2 and −7 (BMP-2, BMP-7) (Grunder et al., 2004; Reddi, 2003; 
Chubinskaya et al., 2007; Flechtenmacher et al., 1996), and transforming growth factor 
beta1 (TGF-β1) (Morales and Roberts, 1988; Rosier, O’Keefe et al., 1989). Delivered as 
exogenous proteins or as endogenous proteins by gene transfer in vitro, each of these growth 
factors is anabolic and/or mitogenic. In vivo, each of these factors improves the repair of 
articular cartilage damage (Sellers et al., 1997; Chubinskaya et al., 2007; Fujimoto et al., 
1999; Cucchiarini et al., 2005; Goodrich et al., 2007; Madry et al., 2005; Nixon et al., 1999; 
Yokoo et al., 2005; Rey-Rico et al., 2017). These growth factors also selectively interact to 
synergistically augment articular chondrogenic functions (Shi et al., 2012; Shi et al., 2013).
An anabolic or mitogenic stimulus that simultaneously decreases catabolic activity could be 
more beneficial than a factor that acts only to promote repair or to inhibit degradation. This 
study tests the hypothesis that growth factors known to be anabolic for articular 
chondrocytes are also anti-catabolic.
Articular cartilage degradation in osteoarthritis is thought to be mediated by catabolic 
enzymes and cytokines. Prominent among these are disintegrin and metalloproteinase with 
thrombospondin motifs-4 and −5 (ADAMTS-4 and ADAMTS- 5), also known as 
aggrecanase-1 and aggrecanases-2 (Tortorella et al., 1999; Abbaszade et al., 1999), matrix 
metalloproteinase-3 and −13 (MMP-3 and MMP-13) (Flannery et al., 1992;Goldring et al., 
2011; Mitchell et al., 1996; Tetlow et al., 2001), and interleukin-6 (IL-6) (Qu et al., 2015).
ADAMTS-4 and ADAMTS-5 cleave aggrecan at the ADAMTS cleavage site in the 
interglobular domain of its core protein, and cleavage products from this site are prevalent in 
OA. Removal of ADAMTS-5 (but not ADAMTS-4) by gene knock-out in the mouse 
protects against the development of cartilage damage. Additional data suggest that, in 
contrast to the mouse, ADAMTS-4 is at least as important as ADAMTS-5 in human OA 
(Dancevic and McCulloch, 2014).
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MMP-3 and MMP-13 are increased in OA cartilage (Tetlow et al., 2001) and, like 
ADAMTS-4 and ADAMTS-5, are upregulated by inflammatory cytokines. They cleave 
aggrecan at a site in the interglobular domain that is distinct from that of the aggrecanases 
(Hughes et al., 1998). Unlike the aggrecanases, MMP-3 and MMP-13 also both cleave type 
II collagen. MMP-13 is the principal collagenase for type II collagen in joints, and may be 
more important in OA pathology than MMP-3 (Goldring et al., 2011).
IL-6 is an inflammatory cytokine that is elevated in the serum, synovial fluid (Gobezie et al., 
2007; Kokebie et al., 2011), and articular cartilage (Qu et al., 2015) of patients with OA and 
the synovial fluid of patients with articular cartilage defects (Tsuchida et al., 2012). IL-6 
serum levels predict radiographic knee OA (Livshits et al., 2009) and IL6 gene expression is 
increased in knee articular cartilage in OA patients (Qu et al., 2015).
We assessed the growth factor regulation of the gene expression of these catabolic mediators 
by transfecting adult articular chondrocytes with the genes encoding IGF-I, BMP-2, BMP-7, 
TGF-β1 and FGF-2. To our knowledge, this is the first systematic analysis of the regulation 
of catabolic factor gene expression by chondrogenic growth factors. Because the genes 
encoding these growth factors, and the growth factors themselves, are under consideration as 
therapeutic agents for articular cartilage repair, these data are important to their further 
evaluation and development.
Materials and Methods
Construction of IGF-I, FGF-2, BMP-2, BMP-7 and TGF-β1 pAAV vectors
The vectors pAAV-IGF-I, pAAV-FGF-2, pAAV-BMP-2, pAAV-BMP-7 and pAAV-TGF-β1 
were generated as previously described (Shi et al., 2012). Briefly, the human growth factor 
cDNA coding regions were generated by PCR and, after confirming the sequences, were 
subcloned into pAAV-MCS (Stratagene, La Jolla, CA) to obtain the pAAV-based vectors. To 
improve the readability of the data presented, the transgenes carried by pAAV- IGF-I, pAAV-
FGF-2, pAAV-BMP-2, pAAV-BMP-7 and pAAV-TGF-β1 are here designated tIGF-I, 
tFGF-2, tBMP-2, tBMP-7 and tTGF-β1.
Chondrocyte cell culture and transfection
Basal medium was prepared with DMEM, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 
mM glutamine (Invitrogen, Carlsbad, CA) and 50 μg/ml ascorbic acid (Sigma, St. Louis, 
MO). Complete medium was prepared by supplementing basal medium with 10% FBS 
(Invitrogen). Bovine articular chondrocytes were isolated and placed in primary culture as 
previously described (Shi et al., 2010). Briefly, chondrocytes were isolated from the carpal 
joints of skeletally mature (growth plates closed) bovids, cultured at 3 × 105 cells/well in 
complete medium for 3 days, and transfected using FuGENE 6 (Roche Applied Science, 
Indianapolis, IN) and plasmid DNA. For single transfections, 2 μg of each plasmid DNA per 
well was used. For multiple transfections, 2 μg of each plasmid DNA per well was used 
together. Control cells received 2 μg, 4 μg, or 6 μg empty vector DNA for 1-, 2-, and 3-
transgene transfections respectively. Transfection was stopped by replacing the medium with 
fresh complete medium. On days 2 and 4 after transfection, conditioned medium (CM) was 
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collected and replaced by basal medium. On day 6 after transfection, CM was collected and 
cell culture was terminated. At daily intervals, triplicate samples of chondrocytes were lysed 
with lysis buffer RLT (RNeasy Mini kit, Qiagen, Valencia, CA), homogenized by passing 6 
times through a 20- gauge needle and stored at −80°C for total RNA purification.
RNA purification, reverse transcription and real-time PCR analysis
RNA purification and reverse transcription were performed as previously described (Shi et 
al., 2009). Briefly, total RNA was prepared using the RNeasy Mini kit (Qiagen). On-column 
DNase digestion was performed to remove any residual DNA. Reverse transcription was 
performed using the High-capacity cDNA Archive Kit (Applied Biosystems, Foster City, 
CA) and random primer. Reverse transcription was terminated by heating at 95°C for 20 
minutes. cDNA samples were used for real-time PCR analysis. Real-time PCR was 
performed as previously described (Shi et al., 2012). Briefly, ADAMTS-4 and −5, MMP-3 
and 13, and IL-6 transcripts, and 18S rRNA content were measured by real-time PCR using 
SYBR Green master mix (Life Technologies) and CFX96 real-time PCR detection system 
(Bio-Rad). Primers were synthesized by Life Technologies (Table 1). The standard curve 
method was used to calculate the expression of target genes encoding ADAMTS-4 
(ADAMTS4), ADAMTS-5 (ADAMTS5), MMP-3 (MMP3), MMP-13 (MMP13), and IL-6 
(IL6), and the content of 18S rRNA. Target gene mRNA levels were normalized to 18S 
rRNA levels. Fold changes of target gene expression were measured as the ratio of 
expression by growth factor gene transfected cells to that of cells transfected with empty 
vector (mock-transfected) control. Three independent experiments were performed using 
articular chondrocytes obtained from different bovine joints at different times. Data are 
presented as the average of fold changes.
Statistical Analysis
The effects of IGF-I, TGF-β1, BMP-2, BMP-7 and FGF-2 gene transfer on outcome 
variables (ADAMTS4, ADAMTS5, MMP3,MMP13 and IL6 expression) were evaluated 
using repeated measures ANOVA. The ANOVAs used terms for group, day, and the group-
by-day interaction, as well as a random effect to correlate data within each of the three 
experimental runs. An unstructured variance/covariance matrix was used for the variances 
and correlations within a sample across the six days. In the case of MMP13 expression, the 
values were through day 5 because day 6 values were below PCR detection. The natural log 
transformation of the measurements was used for the analyses to address skewing of the 
data. No adjustments were made for multiple comparisons. Using the ANOVAs, tests were 
performed to 1) compare the effects of individual growth factor transgenes, 2) compare the 
effects of combinations of multiple, simultaneously delivered transgenes with the effects of 
individual transgenes and with the effects of the other transgene combinations, and 3) 
determine whether multiple gene transfer generated synergistic or inhibitory effects 
compared to the transfer of individual genes. The interaction data are expressed as 
comparisons of ratios of combined to separate effects (C/S ratios), where combined effect is 
the value of the dependent variable in response to the transgene combination, and separate 
effects is the sum of the values of the dependent variable in response to the two independent 
variables. Four types of results were obtained from the interaction analysis: 1) Additive 
effects were those for which the result from the combined transgenes was not significantly 
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different from the sum of the results from the individual transgenes (absence of interaction). 
2) Synergistic effects were those for which the result from the combined transgenes was 
greater than the sum of the results from the individual transgenes (C/S > 1). 3) Inhibitory 
effects were those for which the result from the combined transgenes was reduced compared 
to the sum of the results from the individual transgenes (C/S < 1.0). Inhibition occurred 
when a.) C and S were both greater than control (positive values), b.) C was less than S (the 
combined transgenes had a reduced increase compared to the sum of the individual 
transgenes), c.) C and S were both less than control (negative values), or d.) the absolute 
value of the decrease by C was less than that of S (the combined transgenes had less of a 
decrease compared to the sum of the individual transgenes). 4) Synergistically inhibitory 
effects were those for which the sum of the results from the individual transgenes was less 
than control, and the result from the combined transgenes was less than this sum (Shi et al., 
2013). A 5% significance level was used for all comparisons. The term inhibitory is used 




All individual growth factor transgenes stimulated ADAMTS4 expression compared to 
mock-transfected controls. The IGF-I and FGF-2 transgenes (tIGF-1 and tFGF-2) each 
increased ADAMTS4 expression more than two-fold and maintained stimulation for the 6- 
day duration of the experiments. Stimulation by the other individual transgenes was transient 
and was never greater than 2-fold (Figure 1A). All combinations of growth factor transgenes 
generated a biphasic time course, characterized by peak stimulation at day 3 or 4 and 
followed by a partial return toward baseline. Maximal stimulation of ADAMTS4 was 15.6-
fold (p<0.0001) by the combination [tIGF-I + tFGF-2]. No transgene combination reduced 
ADAMTS4 below control levels at any time point (Figure 1B).
The growth factor transgenes interacted in a complex fashion, ranging from inhibitory to 
synergistic. In all cases, this interaction followed a time course from no interaction to 
inhibition to synergistic stimulation of ADAMTS4 expression. The duration of the 
synergistic stimulation varied from the full remainder of the study period, as for the 
combination [tIGF-I + tFGF-2], to only one day, as for [tIGF-I + tFGF-2+ tBMP-7], after 
which the interactions became inhibitory again. Maximum synergy was obtained by 
combining tIGF-I and tFGF-2(C/S=4.39, p<0.0001). Maximum inhibition occurred when 
tBMP-7 was added to [tIGF-I + tFGF-2] (C/S=0.54, p<0.0001) (Tables 2 and 3).
ADAMTS5 Expression:
All individual growth factor transgenes decreased ADAMTS5. The time course of the 
decrease in ADAMTS5 expression varied from progressive decrease over time for tTGF-β1, 
to minimal change for tIGF-I, to diminishing effect over time for tBMP-2 and tBMP-7 
(Figure 2A). Of the transgene combinations, [tIGF-I + tBMP-2 + tBMP-7] caused the 
greatest reduction (96%, p<0.0002) in ADAMTS5 expression compared to control. Only 
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tFGF-2 increased ADAMTS5, a transient increase to 1.3 fold control on day 3 (p = 0.0161)
(Figure 2B).
Several growth factor transgenes interacted in inhibiting ADAMTS5 expression. Notably, 
when tIGF-I was added to either tFGF-2 or tTGF-β1, the combination [tIGF-I + tFGF-2] or 
[tIGF-I + tTGF-β1] synergistically inhibited ADAMTS5 expression at five of the six time 
points tested. Maximum synergistic inhibition (C/S = 2.68, p<0.0001) was generated by 
combining tIGF-I and tFGF-2 (Tables 2 and 3).
MMP3 Expression:
Most individual transgenes had little effect on MMP-3 expression. An exception, tFGF-2, 
increased MMP3 expression to 7.7-fold (p=0.001) on day 4 and maintained a greater than 4-
fold stimulation throughout the remainder of the culture period. Only tIGF-I and tTGF-β1 
reduced MMP3 expression below control levels, tIGF-I transiently to 75% (p=0.0203) and 
tTGF-β1 progressively to 54% (p=0.0258) of control (Figure 3A). Transgene combinations 
generally followed a biphasic time course characterized by increasing stimulation for 3–4 
days, followed by a return toward control levels. In contrast, combinations that included both 
tIGF-I and tFGF-2 produced a sustained, >6-fold increase in MMP3 expression. The only 
transgene combination that reduced MMP3 expression to less than control was [tIGF-I + 
tTGF-β1] (Figure 3B).
Interactions among [tIGF-I + tBMP-2] in regulating MMP3 expression led to the largest 
synergistic stimulation observed in these studies (C/S=15.2, p<0.0001). Interestingly, 
because the individual effects of these transgenes were minimal, this interaction generated 
only a 3.22-fold stimulation compared to control. The addition of tIGF-I as a second 
transgene delayed, but did not abrogate, the pronounced MMP3 stimulation by tFGF-2. No 
growth factor transgene overcame the stimulation of MMP3 expression by tFGF-2, and only 
tTGF-β1 as a second transgene succeeded in reducing this stimulation (Tables 2 and 3).
MMP13 expression:
Treatment with tBMP-2, tBMP-7 or tFGF-2 each increased MMP13 expression. The 71- 
fold (p<0.0001) increase in MMP13 expression by tFGF-2 compared to control was the 
largest change observed in these studies. Treatment with tBMP-2 or tBMP-7 increased 
MMP13 expression up to 2.3-fold and 5.3-fold respectively. Treatment with tTGF-β1 
decreased MMP13 expression to 40% of control (p=0.0088). This was the maximum 
reduction in gene expression by an individual growth factor transgene observed in these 
studies. Treatment with tIGF-I initially decreased MMP13 expression, but subsequently 
increased it 2.3 fold (p=0.0213) compared to control (Figure 4A). All growth factor 
transgene combinations that did not include tFGF-2 reduced MMP13 expression to less than 
control levels by day 4 (Figure 4B).
Growth factor transgene interactions markedly altered MMP13 expression. When tIGF-I was 
added to tFGF-2, it reduced the stimulation by tFGF-2 from 71-fold to 5.4-fold (C/S = 0.06, 
p=0.0397). The addition of tFGF-2 to tTGF-β1 overcame the reduction in MMP13 
expression by tTGF-β1 alone. Conversely, tTGF-β1 reduced the stimulation by tFGF-2 from 
71-fold to 22-fold by day five following transfection (C/S=0.30, p<0.0001) (Tables 2 and 3).
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Treatment with tBMP-7 progressively decreased IL6 expression to 41% of control 
(p=0.0155). Treatment with tBMP-2 tended to be inhibitory, but this effect was transient. 
Treatment with tFGF-2, tIGF-I, or tTGF-β1 increased IL6 expression in a time-dependent 
manner to peak values of 10.8 fold, 3.0 fold and 2.4 fold (all p<0.0001) (Figure 5A). All 
growth factor transgene combinations that included tFGF-2 stimulated IL6 expression, while 
all combinations that included a BMP transgene inhibited this expression. (Figure 5B).
Interaction between tIGF-I and tFGF-2 generated a synergistic stimulation of IL6 expression 
to C/S=8.26 (p<0.0001) by day 4, corresponding to a >40-fold increase compared to control. 
In contrast, the addition of any other transgene to tIGF-I was inhibitory, or had no effect, at 
all-time points tested (Tables 2 and 3).
Discussion
We hypothesized that the anabolic and mitogenic actions of chondrogenic growth factors 
would be complemented by a reduction in the expression of chondrocyte genes encoding 
catabolic factors. Our results generally contradict this hypothesis. While certain growth 
factor transgenes and transgene combinations did inhibit catabolic marker genes, most had 
the opposite effect. The data also demonstrate considerable diversity among the five tested 
growth factor transgenes in regulating the expression of the five articular chondrocyte 
catabolic genes investigated in this study. These differences among the treatments included 
their magnitude, time course and interactions. The growth factors were selected on the basis 
of prior demonstration of chondrogenic properties and possible interactions due to 
differences in signal transduction pathways. In addition, the selected growth factor 
transgenes had been previously shown to differentially regulate anabolic functions in 
articular chondrocytes and to interact in doing so (Shi et al., 2013)
All five growth factor transgenes upregulated ADAMTS4 expression and down-regulated 
ADAMTS5 expression at one or more time points. Although the time course differed among 
the growth factor transgenes, no transgene downregulated ADAMTS4 or, with the exception 
of tFGF-2, upregulated ADAMTS5 at any time point. This shared action of all the growth 
factor transgenes was observed only for the ADAMTSs. The finding that all the growth 
factor transgenes and transgene combinations oppositely regulated ADAMTS4 and 
ADAMTS5 expression suggests that ADAMTS-4 and ADAMTS-5 play distinct roles in 
mediating growth factor regulation of articular cartilage homeostasis. The observation that 
ADAMTS 5 knockout mice are resistant to OA while ADAMTS 4 knockout mice remain 
susceptible to OA (Glasson et al., 2004; Glasson et al. 2005) are consistent with such a 
difference. A recent report suggests that the action of these two aggrecanases in OA may 
differ between mice and humans (Dancevic and McCulloch, 2014). It is unknown whether 
their regulation by growth factors is also species- specific. The finding that tFGF-2 
upregulated ADAMTS4 expression, but generally had no significant effect on ADAMTS5 
expression, differs from the inhibition of both ADAMTS4 and ADAMTS5 expression by 
exogenous FGF- 2 noted in a prior report (Sawaji et al., 2008). This difference may reflect 
differences in experimental design, including the use in that study of an IL-1α - stimulated 
human primary chondrocyte model.
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Treatment with tFGF-2 generated a much greater increase in both MMP3 and MMP13 gene 
expression than any of the other growth factor transgenes. The effect of tFGF-2 on MMP13 
expression is consistent with prior studies, but the 71-fold stimulation observed in this study 
is greater than the previously reported 5-fold (Im et al., 2007) and 20-fold (Im et al., 2009) 
stimulation by 100ng/ml exogenous bFGF.
The data reveal an antagonistic relationship between tTGF-β1 and tFGF-2 in the regulation 
of MMP13 expression. Among the individual transgenes tested in this study, tFGF-2 
maximally stimulated, and tTGF-β1 maximally reduced, MMP13 expression. The addition 
of tTGF-β1 to tFGF-2 produced a marked, sustained reduction in the stimulation by tFGF-2 
(C/S=0.3). The finding that the combination [tFGF-2 and tTGF-β1] increased MMP13 
expression 22.4 fold suggests that tFGF-2 is dominant over tTGF-β1 in regulating MMP13. 
Paradoxically, although tIGF-I and tBMP-7 each increased MMP13 expression, each also 
markedly reduced the strong stimulation by tFGF-2 of MMP13 expression, and the addition 
of both tIGF-I and tBMP-7 to tFGF-2 further reduced this expression.
Modulation of IL6 expression in this study included upregulation at multiple time points by 
tTGF-β1, but never downregulation. In contrast, tBMP-7 downregulated, but never 
upregulated IL6 expression. Further, the downregulation of IL6 expression by tBMP-2 was 
transient, while that of tBMP-7 persisted for the duration of the experiments. These data 
indicate that, while these growth factors share membership in the tTGF-β superfamily, they 
do not share all of their regulatory actions on IL6 expression. Treatment with tIGF-I and 
tFGF-2 together generated a striking synergistic stimulation of IL6 expression to C/S=8.26. 
However, the addition of tBMP-7 as a third transgene abrogated this interaction, such that 
IL-6 stimulation by [tFGF-2 + tIGF-I + tBMP-7] was similar to that by tFGF-2 alone.
IGF-I is unusual in the breadth of its cartilage reparative actions. It stimulates both 
chondrocyte proliferation and matrix synthesis, reduces the effect of pro-catabolic and anti- 
anabolic agents, and protects cartilage matrix from endogenous degradation (Sah et al., 
1994; Sah et al., 1996; Tyler, 1989; Montaseri et al., 2011) . The present finding that tIGF-I 
interactions reduced the expression of several catabolic genes supplements existing evidence 
for IGF-I anti- catabolic activity. However, the pro-catabolic stimulation of both ADAMTS4 
and IL6 expression by tIGF-I suggests a potentially more complex role for this growth factor 
in articular cartilage homeostasis.
BMP-2 has been reported to transiently increase aggrecan degradation simultaneously with 
its stimulation of proteoglycan synthesis and aggrecan gene expression in murine knee joints 
(Blaney Davidson et al., 2007). To our knowledge, BMP-7 has not been shown to promote 
catabolic activity by articular chondrocytes. The present studies suggest that tBMP-2 and 
tBMP-7 can each stimulate the expression of ADAMTS4, MMP3 and MMP13, though to 
only a modest degree. They can also interact with tIGF-I to increase ADAMTS4 and MMP3.
As hypothesized, several growth factor transgenes and transgene combinations did reduce 
the expression of the tested catabolic marker genes. All individual growth factor transgenes, 
except tFGF-2, decreased ADAMTS5 expression. Similarly, all transgene combinations, 
except [tFGF-2 + tTGF-β1], inhibited ADAMTS5 expression. Treatment with tTGF-β1 
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generated a sustained decrease in MMP13 expression, but this was the only individual 
growth factor transgene to do so. All interactions among transgenes inhibited MMP13 
expression, even when the effect of the combination was positive compared to controls. 
Among individual growth factor transgenes, only tBMP-7 caused a sustained decrease in IL6 
expression. It also produced a marked inhibition of IL6 expression (C/S ratios 0.14 – 0.32) 
when delivered in combination with tIGF-I and tFGF-2, though the tBMP-7 did not 
overcome the stimulatory effect of tIGF-I and tFGF-2 compared to controls (Tables 2 and 3). 
In general, the hypothesis tended to be supported most by tTGF-β and tBMP-7 and least by 
tFGF-2.
These data suggest a mechanism by which these growth factor transgenes regulate 
chondrocyte matrix production. A previous study (Shi et al., 2013) found that these growth 
factor transgenes regulated not only the synthesis of cartilage matrix molecules, but also 
their distribution. Specifically, the growth factor transgenes differentially regulated the 
proportion of matrix molecules deposited in the cell layer compared to those disbursed into 
the medium. This ratio of retained to released glycosaminoglycan (GAG) and collagen is 
important to cartilage repair because the retained GAG and collagen contribute to new tissue 
formation, while the released molecules are lost. The present data may lend insight into 
those findings. Among the tested growth factor transgenes, tFGF-2 generated the greatest 
stimulation of ADAMTS4, MMP3, MMP13 and IL6 expression, and tFGF-2 plus tIGF-I 
synergistically stimulated ADAMTS4 and IL6 expression. In the prior studies, of all these 
transgenes, tFGF-2 generated the lowest ratio of retained to released GAG and collagen, and 
this ratio was further lowered by interaction between tFGF-2 with tIGF-I (Shi et al., 2013). 
These data suggest that the reduced retention of newly synthesized matrix molecules reflects 
a stimulation by FGF-2 and FGF-2 + IGF-I of catabolic gene expression. Further, in the 
present study, the combination [tIGF-I + tBMP-2 + tBMP-7] reduced the expression of three 
of the five chondrocyte genes (ADAMTS5, MMP13 and IL6) to a greater degree than any of 
the other growth factor transgenes or transgene combinations. In the prior studies, the 
combination [tIGF-I + tBMP-2 + tBMP-7] generated the highest GAG ratio and highest 
collagen ratio of any growth factor transgene or transgene combination tested (Shi et al., 
2013). Taken together, these data suggest that growth factor regulation of chondrocyte 
catabolic activities may help determine the retention or loss of the matrix molecules whose 
production is regulated by the growth factors. In this event, the regulation of catabolic 
chondrocyte genes may contribute to the efficacy of the growth factors in articular cartilage 
engineering and repair, where matrix deposition is a key determinant of success.
The observation that anabolic growth factor gene overexpression increases catabolic gene 
expression may reflect a feedback mechanism. Alternatively, or in addition, these dual roles 
may contribute to tissue remodeling. The wide range of actions and interactions of these 
growth factor transgenes on each of the target genes, and the differences in the regulation of 
the different target genes by the different growth factor transgenes and transgene 
combinations, offer a potentially tunable system for modulating the balance between 
mitogenic, anabolic, and catabolic gene expression in these cells.
The observation that chondrocyte genes that serve similar functions (eg MMP3 and 
MMP13) are differentially regulated by these growth factors are not readily interpreted at a 
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mechanistic level. For example, the effect of FGF-2 on these enzymes may be mediated, at 
least in part, by the regulation by FGF-2 of IL-6. The mechanisms underlying the 
interactions identified in this study remain to be elucidated. Further studies will be needed to 
define the specific pathways and networks through which the growth factors act and interact 
in regulating the expression of these genes and their protein products.
A strength of the study is the relatively large number of growth factor and catabolic genes 
tested. The growth factors possess known reparative actions on articular chondrocytes, and 
the regulated genes encode catabolic factors that play a role in cartilage degradation in OA. 
However, a limitation of the study is that other anabolic and catabolic factors are also likely 
to be involved in the disease process and may have therapeutic potential. For example, 
vascular endothelial growth factor (VEGF) influences chondrocytes and may interact with 
FGF-2, with which it shares a vascular regulatory function that may be involved in OA 
pathogenesis.
A further limitation of this study is its focus on gene expression. Assessment of the amount, 
location and fate of the endogenous growth factors is beyond the scope of this study. While 
the regulation of gene expression is a key step in chondrocyte function, further studies will 
be required to elucidate the post- transcriptional processing events that influence their 
contribution to cartilage homeostasis.
Taken together, these data indicate that growth factors that are traditionally viewed as 
chondrogenic appear to also regulate catabolic activity. The complex interplay among these 
growth factor transgenes was not predictable based on their individual actions. For these 
reasons, the selection of regulatory factors for articular cartilage repair may be more 
complex than previously thought. Empirical studies will likely be needed to optimize growth 
factor therapy for clinical application.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Effect of individual (A) and multiple (B) growth factor gene transfer on the expression of 
ADAMTS4 expression by adult articular chondrocytes over time. Values reflect the ratio of 
treated to control ADAMTS4 mRNA levels in response to the designated transgene(s) at the 
designated time points. To illustrate ratios that are >1.0 and those that are <1.0, the data is 
presented as the natural log (ln) of the value and the y-axes are scaled to accommodate the 
magnitude of change. Data represent the mean of n=3 independent experiments. 95% 
confidence intervals and p-values compared to control are provided in Table S1. P-values for 
comparisons between groups and for comparisons between days are presented in STable 4 
and STable 5 respectively.
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Effect of individual (A) and multiple (B) growth factor gene transfer on the expression of 
ADAMTS5 expression by adult articular chondrocytes over time. Values reflect the ratio of 
treated to control ADAMTS5 mRNA levels in response to the designated transgene(s) at the 
designated time points. To illustrate ratios that are >1.0 and those that are <1.0, the data is 
presented as the natural log (ln) of the value and the y-axes are scaled to accommodate the 
magnitude of change. Data represent the mean of n=3 independent experiments. 95% 
confidence intervals and p-values compared to control are provided in STable 3. P-values for 
comparisons between groups and for comparisons between days are presented in STable 4 
and STable 5 respectively.
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Effect of individual (A) and multiple (B) growth factor gene transfer on the expression of 
MMP13 expression by adult articular chondrocytes over time. Values reflect the ratio of 
treated to control MMP13 mRNA levels in response to the designated transgene(s) at the 
designated time points. To illustrate ratios that are >1.0 and those that are <1.0, the data is 
presented as the natural log (ln) of the value and the y-axes are scaled to accommodate the 
magnitude of change. Data represent the mean of n=3 independent experiments. 95% 
confidence intervals, and p-values compared to control are provided in STable 3. P-values 
for comparisons between groups and for comparisons between days are presented in STable 
4 and STable 5 respectively.
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Effect of individual (A) and multiple (B) growth factor gene transfer on the expression of 
MMP3 expression by adult articular chondrocytes over time. Values reflect the ratio of 
treated to control MMP3 mRNA levels in response to the designated transgene(s) at the 
designated time points. To illustrate ratios that are >1.0 and those that are <1.0, the data is 
presented as the natural log (ln) of the value and the y-axes are scaled to accommodate the 
magnitude of change. Data represent the mean of n=3 independent experiments. 95% 
confidence intervals and p-values compared to control are provided in STable 3. P-values for 
comparisons between groups and for comparisons between days are presented in STable 4 
and STable 5 respectively.
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Effect of individual (A) and multiple (B) growth factor gene transfer on the expression of 
IL6 expression by adult articular chondrocytes over time. Values reflect the ratio of treated 
to control IL6 mRNA levels in response to the designated transgene(s) at the designated time 
points. To illustrate ratios that are >1.0 and those that are <1.0, the data is presented as the 
natural log (ln) of the value and the y-axes are scaled to accommodate the magnitude of 
change. Data represent the mean of n=3 independent experiments. 95% confidence intervals 
and p-values compared to control are provided in STable 3. P-values for comparisons 
between groups and for comparisons between days are presented in STable 4 and STable 5 
respectively.
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Table 1:
Primers used for real-time PCR
Gene ACC. No. Primer (5’ to 3’)
18S AF176811 Forward: CTGAGAAACGGCTACCACATC
Reverse: GCCTCGAAAGAGTCCTGTATTG
ADAMTS-4 NM_181667 Forward: GAAGCAATGCACTGGTCTGA
Reverse: CTAGGAGACAGTGCCCGAAG
ADAMTS-5 NM_001166515 Forward: TGCAGATTCTTGCCACAGAC
Reverse: CTTTTGGAGCCGACTTCTTG
MMP-3 NM_001206637 Forward: TGTGCTCAGCCTATCCACTG
Reverse: AGCTTTCCTGTCACCTCCAA
MMP-13 NM_174389 Forward: AGGCCTTCAGAAAAGCCTTC
Reverse: CAACAGACCAGAGGGTCCAT
IL-6 EU276071 Forward: CAGCTATGAACTCCCGCTTC
  Reverse: TTCGGTTTTCTCTGGAGTGG
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Table 2.
Summary of interactions among two growth factor transgenes in regulating articular chondrocyte gene 
expression. Chondrocytes were transfected with the designated individual transgenes or transgene 
combinations, and expression of the designated chondrocyte genes after 1 to 6 days were compared. C/S ratio: 
the change in gene expression in response to the combined treatments (C) divided by the sum of the changes in 
gene expression in response to the separate treatments(s). Types of interaction (Int) are designated as follows. 
+ + : synergistic stimulatory interaction in which the result from the combined treatments was greater than the 
sum of the results from the individual treatments (C/S > 1); — : inhibitory interaction in which the result from 
the combined treatments reduced the results from the individual treatments (C/S < 1.0 ); — — : synergistically 
inhibitory interaction in which the sum of the results from the individual treatments was less than control, and 
the result from the combined treatment was less than this sum. * or **: C/S is indeterminate because (*) the 
sum of the individual treatments is less than control but the combined treatments are greater than control or 
(**) the sum of the individual treatments factors is greater than control but the combined treatments are less 
than control. Empty cell: interactive effect did not achieve statistical significance (P ≥ 0.05). All designated 
interactions are statistically significant (P < 0.05). Values represent the mean of three independent 



















1 1.33 ** * * 2.65 + +
2 1.07 + + 1.53 + + 0.41 − 0.39 − **
3 0.92 − 0.21 0.67 − 0.66 − 1.26 + +
4 2.19 + + 0.18 0.72 − 0.41 − 2.23 + +
5 1.59 + + 0.25 − 0.34 − 0.30 − 0.59 −




1 0.34 0.84 − 1.98 − − 2.16 ** −
2 0.83 − 0.76 − 0.24 0.03 0.68 −
3 1.32 + + 0.94 − 15.24 + + ** 0.96 −
4 1.79 + + 1.18 − − * ** **
5 0.69 − 1.66 − − * ** **




1 0.40 1.02 − − 0.38 * 1.85
2 0.89 − 0.75 − 0.53 − 0.36 0.56 −
3 1.32 + + 0.95 − 8.02 + + 0.39 0.74
4 2.04 + + 1.07 − − 6.57 + + ** **
5 1.11 + + 1.78 − − 0.68 ** **




1 0.63 1.83 − − * * 0.78 −
2 0.82 − 1.82 − − 0.05 0.34 − 0.68 −
3 1.51 + + ** − 0.17 − 0.15 − 1.29 + +
4 3.93 + + 2.68 − − 0.97 − 0.06 8.26 + +
5 4.39 + + 2.20 − − 1.22 + + 0.06 − 2.93 + +
6 2.66 + + 1.91 − − 1.08 + + 4.83 + +
































1 ** 1.32 − − 0.17 * 0.98 −
2 0.53 − 1.02 − − 0.23 0.29 0.53
3 0.67 − 1.11 − − 3.03 + + 0.43 *
4 1.50 + + 1.06 − − * 2.34 0.38
5 1.20 + + 1.09 − − 0.25 ** 0.31
6 1.14 + + 0.95 − ** 0.16
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Table 3.
Summary of interactions among three growth factor transgenes in regulating articular chondrocyte gene 
expression. Chondrocytes were transfected with the designated individual transgenes or transgene 
combinations, and expression of the designated chondrocyte genes after 1 to 6 days was compared. Data 
represent the mean of the three independent experiments as described in Table 2. Results are expressed as in 
Table 2. Detailed data are presented in STable 2.
Growth Factor
Transgene Comparisons Day














1 0.25 0.80 − 0.67 − ** 14.52 − −
2 0.73 − 0.52 − 0.18 − ** − 0.64 −
3 1.39 + + 0.61 − 4.24 + + ** 0.70 −
4 2.29 + + 0.77 − 13.61 + + ** 4.32
5 1.21 + + 1.24 − − 6.20 + + ** **




1 0.70 0.94 − 0.46 − ** 0.37 −
2 0.85 − 0.63 − 0.32 − ** − 0.86 −
3 1.09 + + 0.63 − 1.02 + + ** 0.72 −
4 1.27 + + 0.70 − 3.09 + + ** 0.67
5 1.70 + + 0.87 − 1.22 + + ** 0.30




1 0.44 0.79 − 5.61 − − ** ** −
2 0.79 − 0.62 − 0.24 − ** − 0.79 −
3 1.11 + + 0.63 − 1.05 + + ** 0.80 −
4 1.17 + + 0.74 − 2.30 + + ** 0.78
5 1.11 + + 0.82 − 12.79 + + ** 0.67




1 ** 1.58 − − * * 1.35 + +
2 0.70 − 0.88 − 0.12 − ** − 0.31 −
3 1.99 + + 1.26 − − 0.54 − 0.09 − 1.86 + +
4 2.66 + + 1.08 − − 0.63 − 0.03 2.82 + +
5 2.29 + + 1.36 − − 0.86 − 0.04 0.44 −




1 ** 0.91 − * * 2.13 + +
2 0.82 − 0.67 − 0.41 − ** − 0.40 −
3 1.35 + + 0.59 − 1.72 + + 0.40 − 1.41 + +
4 0.67 − 0.65 − 0.65 − 0.24 0.32 −
5 0.54 − 0.80 − 0.71 − 0.54 0.14 −




1 ** 1.53 − − * 0.95 1.17 + +
2 0.75 − 1.25 − − 0.14 − ** − 0.42 −
3 1.72 + + 1.36 − − 0.32 − 0.10 − 1.79 + +
4 1.96 + + 1.01 − − 0.56 − 0.04 3.39 + +
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Growth Factor
Transgene Comparisons Day











5 2.16 + + 0.86 − 0.87 − 0.04 0.50 −
6 1.46 + + 0.96 − 2.24 + + 1.36 + +
J Cell Biochem. Author manuscript; available in PMC 2020 August 27.
